Hangzhou Sumgen Biotech Co., Ltd.
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung CancerCervical Cancer | |
| Phase 3 | CD38Monoclonal antibody | Multiple MyelomaSystemic Lupus Erythematosus | |
| Phase 1/2 | LILRB4 (ILT3)Antibody–drug conjugate | Multiple Myeloma |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (6)
March 2027 (2)
April 2027 (1)
Est. primary completion 2027-04 · NCT06136988 · CT.gov ↗
What to watch
May 2027 (1)
Est. primary completion 2027-05-17 · NCT07710248 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Est. primary completion 2028-06-26 · NCT07282509 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.